Another phase II clinical trial (NCT03610516) will test the role of CFZ533 (a humanized anti-CD40 monoclonal antibody) in LN patients who show persistent significant proteinuria after standard induction treatments. This evidence concerns the gene CD40 and lobular neoplasia.